Bradley Foster & Sargent Inc. CT Buys 40 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bradley Foster & Sargent Inc. CT raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,896 shares of the pharmaceutical company’s stock after buying an additional 40 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Vertex Pharmaceuticals were worth $889,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in VRTX. Aveo Capital Partners LLC lifted its stake in Vertex Pharmaceuticals by 77.3% in the fourth quarter. Aveo Capital Partners LLC now owns 1,076 shares of the pharmaceutical company’s stock valued at $438,000 after buying an additional 469 shares during the period. Gryphon Financial Partners LLC raised its position in shares of Vertex Pharmaceuticals by 26.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 1,978 shares of the pharmaceutical company’s stock worth $805,000 after purchasing an additional 414 shares during the period. Brown Advisory Inc. raised its position in shares of Vertex Pharmaceuticals by 25.0% during the fourth quarter. Brown Advisory Inc. now owns 3,522 shares of the pharmaceutical company’s stock worth $1,433,000 after purchasing an additional 705 shares during the period. Trexquant Investment LP raised its position in shares of Vertex Pharmaceuticals by 161.2% during the fourth quarter. Trexquant Investment LP now owns 3,968 shares of the pharmaceutical company’s stock worth $1,615,000 after purchasing an additional 2,449 shares during the period. Finally, Quest Partners LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $33,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on VRTX. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, July 26th. Piper Sandler upped their target price on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. BMO Capital Markets upped their price target on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, May 31st. Redburn Atlantic initiated coverage on Vertex Pharmaceuticals in a report on Thursday, June 27th. They set a “buy” rating and a $545.00 price target for the company. Finally, Truist Financial reiterated a “buy” rating and set a $550.00 price target (up previously from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $486.36.

Vertex Pharmaceuticals Stock Up 0.8 %

VRTX stock opened at $477.90 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. The company has a market capitalization of $123.32 billion, a price-to-earnings ratio of 31.01 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $341.85 and a fifty-two week high of $510.64. The stock has a fifty day moving average of $483.14 and a 200-day moving average of $451.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The firm had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.53 EPS. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current year.

Insider Transactions at Vertex Pharmaceuticals

In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now directly owns 4,435 shares in the company, valued at approximately $2,217,500. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,047 shares of company stock worth $16,843,806. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.